Abbott Laboratories Sells Agricultural Products Business to Sumitomo Chemical Co., Ltd.

Strategic Insights -

Abbott Laboratories, a global, diversified health care company, has reached an agreement to sell its agricultural products business to Sumitomo Chemical Co., Ltd. of Tokyo, Japan. This strategic move allows Abbott to focus on the growth of its core health care businesses, while Sumitomo acquires research and development, sales, marketing, and support operations for Abbott's entire line of naturally- occurring biopesticides, plant growth regulators, and other products. The transaction is subject to customary closing conditions and regulatory approval and is expected to be completed in January 2000.

Key Takeaways:

  • Abbott Laboratories has sold its agricultural products business to Sumitomo Chemical Co., Ltd. of Tokyo, Japan, further diversifying the latter's portfolio.
  • The transaction includes the transfer of research and development, sales, marketing, and support operations for Abbott's entire line of naturally- occurring biopesticides, plant growth regulators, and other products.
  • Bulk active ingredient manufacturing rights were retained by Abbott, indicating that the company still maintains significant control over the production process.
  • The sale is subject to customary closing conditions and regulatory approval, emphasizing the need for Abbott to comply with relevant laws and regulations.
  • Chen J.K., chairman of Sumitomo Chemical Co., Ltd., has been instrumental in facilitating this acquisition, highlighting the company's commitment to expanding its agricultural products portfolio.
  • Abbott Laboratories, a 56,000-employee company, has successfully navigated this transaction while maintaining its core health care businesses.
  • The transaction's financial terms have not been disclosed, indicating a strategic decision rather than a purely financial one.

Statistics:

  • Abbott Laboratories employs 56,000 people globally.
  • The company markets its products in more than 130 countries, demonstrating its extensive international reach.
  • In 1998, Abbott Laboratories reported $12.5 billion in sales and $2.3 billion in net earnings.
  • Diluted earnings per share for 1998 were $1.51, indicating a robust financial performance.
  • The transaction is expected to be completed in January 2000, providing a timeline for stakeholders to understand the completion date.

Sources:

  • Abbott Laboratories press release, November 11, 1999
  • PRNewswire, November 11, 1999
  • Abbott Laboratories' website (http://www.abbott.com) - Reference to 1998 sales and earnings statistics.